Open AccessLonger-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]
Author(s) -
John G.F. Cleland,
JeanClaude Daubert,
Erland Erdmann,
Nicholas Freemantle,
Daniel Gras,
Lukas Kappenberger,
Luigi Tavazzi
Publication year - 2006
Publication title -
european heart journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.336
H-Index - 293
eISSN - 1522-9645
pISSN - 0195-668X
DOI - 10.1093/eurheartj/ehl099
Subject(s) - medicine , heart failure , cardiac resynchronization therapy , hazard ratio , interquartile range , cardiology , ejection fraction , randomized controlled trial , confidence interval
The CArdiac REsynchronization-Heart Failure study randomized patients with left ventricular ejection fraction < or =35%, markers of cardiac dyssynchrony, and persistent moderate or severe symptoms of heart failure despite pharmacological therapy, to implantation of a cardiac resynchronization therapy (CRT) device or not. The main study observed substantial benefits on morbidity and mortality during a mean follow-up of 29.4 months [median 29.6, interquartile range (IQR) 23.6-34.6]. Prior to study closure, an extension phase lasting a further 8 months (allowing time for data analysis and presentation) was declared during which cross-over was discouraged.